Acetazolamide as an Adjunct to Positive Airway Pressure Therapy in the Treatment of Combined Central and Obstructive Sleep Apnea DOI

Steven C. Scherping,

Mark Quigg, Eric M. Davis

et al.

Annals of the American Thoracic Society, Journal Year: 2022, Volume and Issue: 20(1), P. 131 - 135

Published: Dec. 31, 2022

"Acetazolamide as an Adjunct to Positive Airway Pressure Therapy in the Treatment of Combined Central and Obstructive Sleep Apnea." Annals American Thoracic Society, 20(1), pp. 131–135

Language: Английский

Endorsement of “European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea” by World Sleep Society DOI
Ofer Jacobowitz, Lamia Afifi, Uri Alkan

et al.

Sleep Medicine, Journal Year: 2023, Volume and Issue: 113, P. 293 - 298

Published: Nov. 28, 2023

Language: Английский

Citations

5
A case of middle-aged central sleep apnea due to Joubert syndrome with different treatment effects of oxygen and acetazolamide DOI

Ryoko Murashima,

Satomi Shiota,

Ai Sugiyama

et al.

Journal of Clinical Sleep Medicine, Journal Year: 2024, Volume and Issue: 20(10), P. 1705 - 1710

Published: June 25, 2024

We report a case of severe central sleep apnea incidentally diagnosed during polysomnography for suspected obstructive apnea. Characteristic clinical features included episodic hyperventilation followed by from hypocapnia, which did not follow Cheyne-Stokes pattern. Combined with the identification cerebellar and brainstem malformations known as "molar tooth sign" on brain magnetic resonance imaging, developmental delay, motor coordination problems, Joubert syndrome (a congenital disease) was first at age 50 years. Central apneas were also observed wakefulness, although continuously. During sleep, continuous positive airway pressure adaptive servo-ventilation ineffective referring clinic our hospital. Supplemental oxygen decreased frequency significantly shortened duration each compared room air. In contrast, opposite response acetazolamide administration.

Language: Английский

Citations

1
Using Cannabis and CBD to Sleep: An Updated Review DOI
Isobel Lavender, Gill Garden, Ronald R. Grunstein

et al.

Current Psychiatry Reports, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 29, 2024

Language: Английский

Citations

1
Drug Therapy for Obstructive Sleep Apnea: Are We There Yet? DOI Creative Commons
Christopher N. Schmickl, Bradley A. Edwards, Atul Malhotra

et al.

American Journal of Respiratory and Critical Care Medicine, Journal Year: 2022, Volume and Issue: 205(12), P. 1379 - 1381

Published: March 23, 2022

Language: Английский

Citations

6
Pharmacological management of co-morbid obstructive sleep apnoea and insomnia DOI
Emma E. Thomas, Gorica Micic, Robert Adams

et al.

Expert Opinion on Pharmacotherapy, Journal Year: 2023, Volume and Issue: 24(18), P. 1963 - 1973

Published: Dec. 12, 2023

Introduction Clinical presentation of both insomnia and obstructive sleep apnea (COMISA) is common. Approximately 30% clinical cohorts with OSA have symptoms vice versa. The underlying pathophysiology COMISA multifactorial. This poses a complex challenge. Currently, there are no guidelines or recommendations outside continuous positive airway pressure (CPAP) therapy cognitive behavioral for (CBTi). Clinically translatable precision medicine approaches to characterize individual causes endotypes may help optimize future pharmacological management COMISA.

Language: Английский

Citations

2
The Neurological Spectrum for Acetazolamide Pharmacotherapy: from Basic Science to Clinical Applications DOI
Nevio Cimolai

SN Comprehensive Clinical Medicine, Journal Year: 2021, Volume and Issue: 3(12), P. 2576 - 2592

Published: Nov. 8, 2021

Language: Английский

Citations

5
Unexplained Significant Central Sleep Apnea in Infants: Clinical Presentation and Outcomes DOI
Lena Xiao, Kanokkarn Sunkonkit, Jackie Chiang

et al.

Sleep And Breathing, Journal Year: 2022, Volume and Issue: 27(1), P. 255 - 264

Published: April 11, 2022

Language: Английский

Citations

3
Acetazolamide for central sleep apnea: teaching an old drug new tricks? DOI Open Access
Lee K. Brown

Journal of Clinical Sleep Medicine, Journal Year: 2021, Volume and Issue: 17(6), P. 1153 - 1155

Published: April 1, 2021

Language: Английский

Citations

3
Obstruktive Schlafapnoe: Klug entscheiden, das Richtige tun DOI Creative Commons

B. A. Stuck,

C. Schöbel,

Alfred Wiater

et al.

Somnologie - Schlafforschung und Schlafmedizin, Journal Year: 2021, Volume and Issue: 25(4), P. 294 - 300

Published: Nov. 22, 2021

Zusammenfassung Die obstruktive Schlafapnoe (OSA) kann zu einer erheblichen Einschränkung der Lebensqualität führen, und eine nicht behandelte mittel- bis schwergradige OSA (Apnoe-Hypopnoe-Index ≥ 15/h) erhöht das Risiko vieler – überwiegend kardiovaskulärer Erkrankungen deutlich. In Anbetracht Häufigkeit des Krankheitsbilds damit verbundenen Beeinträchtigungen ist effektive Diagnostik Therapie von besonderer Bedeutung. Deutsche Gesellschaft für Schlafforschung Schlafmedizin (DGSM) hat daher jeweils fünf praxisnahe Positiv- Negativempfehlungen zusammengestellt, die diagnostische therapeutische Vorgehen bei erleichtern sollen. Sie beziehen sich insbesondere auf Indikationen zur schlafmedizinischen spezifischen Therapieoptionen unter Berücksichtigung Alter, Klinik, Risikofaktoren Komorbiditäten. Auswahl Empfehlungen orientiert an klinischen Relevanz, bestehenden Defiziten im Sinne Über- oder Unterversorgung Stärke in aktuellen S3-Leitlinie DGSM den schlafbezogenen Atmungsstörungen.

Citations

3
CPAP, Bilevel, APAP, High and Low Loop Gain Syndromes DOI
Robert J. Thomas

Springer eBooks, Journal Year: 2023, Volume and Issue: unknown, P. 595 - 656

Published: Jan. 1, 2023

Language: Английский

Citations

0